Key clinical point: Risankizumab demonstrated long-term (52 weeks) efficacy in reducing disease severity and showed a consistent safety profile in patients with psoriatic arthritis (PsA) and previous inadequate response or intolerance to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).
Major finding: Among patients who received risankizumab continuously, those achieving ≥20% improvement in American College of Rheumatology (ACR20) response increased from 57.3% at week 24 to 70.0% at week 52; meanwhile, 63.0% of patients who switched from placebo to risankizumab achieved ACR20 at week 52. No new safety signals were identified.
Study details : Findings are from the ongoing phase 3 KEEPsAKE 1 study including 964 patients with active PsA who were csDMARD-IR and were randomly assigned to receive risankizumab or placebo for 24 weeks, of which 940 patients were eligible to receive open-label risankizumab through 208 weeks.
Disclosures: This study was funded by AbbVie. Four authors declared being employees or holding stock options in AbbVie, and the other authors reported ties with several sources, including AbbVie.
Source: Kristensen LE et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2022 (Oct 25). Doi: 10.1093/rheumatology/keac607